Article info
PDFPostScript
Letter
Risk of severe illness from COVID-19 in patients with metabolic dysfunction-associated fatty liver disease and increased fibrosis scores
- Correspondence to Professor Giovanni Targher, Department of Medicine, Endocrinology and Metabolism, University of Verona, Verona 37126, Italy; giovanni.targher{at}univr.it; Professor Ming-Hua Zheng, MAFLD Research Center, Department of Hepatology, The First Affiliated Hospital of Wenzhou Medical University, No 2 Fuxue Lane, Wenzhou 325000, China; zhengmh{at}wmu.edu.cn
Citation
Risk of severe illness from COVID-19 in patients with metabolic dysfunction-associated fatty liver disease and increased fibrosis scores
Publication history
- Received April 28, 2020
- Revised May 4, 2020
- Accepted May 6, 2020
- First published May 15, 2020.
Online issue publication
April 15, 2021
Article Versions
- Previous version (15 April 2021).
- Previous version (15 April 2021).
- Previous version (15 April 2021).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ. This article is made freely available for use in accordance with BMJ’s website terms and conditions for the duration of the covid-19 pandemic or until otherwise determined by BMJ. You may use, download and print the article for any lawful, non-commercial purpose (including text and data mining) provided that all copyright notices and trade marks are retained.https://bmj.com/coronavirus/usage